Hormonal
Perilipin acts as a dynamic scaffold on adipocyte lipid droplets that restricts basal lipolysis by blocking cytosolic lipase access, and upon PKA phosphorylation during energy deficit, facilitates maximal lipolysis by coordinating the docking of hormone-sensitive lipase and adipose triglyceride lipase.
Your body uses a protein called perilipin to manage fat storage. When you are not exercising or fasting (basal state), perilipin acts as a shield, preventing enzymes from breaking down stored fat. When you create an energy deficit (e.g., through exercise or fasting), hormones trigger a signal (PKA) that phosphorylates perilipin. This changes its shape, removing the shield and allowing fat-burning enzymes (ATGL and HSL) to access and break down the fat. Without this protein's dynamic regulation, your body cannot efficiently switch between storing and burning fat.
Under basal conditions, perilipin restricts the access of cytosolic lipases to lipid droplets and thus promotes triacylglycerol storage. In times of energy deficit, perilipin is phosphorylated by PKA and facilitates maximal lipolysis by hormone-sensitive lipase and adipose triglyceride lipase.
Why this rating
Supported by multiple knockout mouse studies, mutagenesis, and biochemical assays cited in the review.
Source
Thematic review series: Adipocyte Biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis
Dawn Brasaemle · Journal of Lipid Research · 2007
DOI 10.1194/jlr.r700014-jlr200
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →